Trials / Conditions / Dyskeratosis Congenita

Dyskeratosis Congenita

17 registered clinical trials studyying Dyskeratosis Congenita — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Nucleoside Therapy in Patients With Telomere Biology Disorders NCT06817590	Suneet Agarwal	Phase 1
Completed	Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Bio NCT04959188	National Cancer Institute (NCI)	—
Terminated	The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Heal NCT04638517	The University of Queensland	Phase 2
Recruiting	Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Ma NCT04232085	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
Recruiting	Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders NCT03579875	Masonic Cancer Center, University of Minnesota	Phase 2
Recruiting	Familial Investigations of Childhood Cancer Predisposition NCT03050268	St. Jude Children's Research Hospital	—
Recruiting	Investigation of the Genetics of Hematologic Diseases NCT02720679	St. Jude Children's Research Hospital	—
Completed	Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia NCT02162420	Masonic Cancer Center, University of Minnesota	N/A
Completed	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases NCT01917708	Emory University	Phase 1
Active Not Recruiting	Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita NCT01659606	Boston Children's Hospital	Phase 2
Terminated	Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation NCT01319851	Emory University	N/A
Terminated	Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita NCT01001598	Boston Children's Hospital	Phase 1 / Phase 2
Completed	Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA NCT00455312	Masonic Cancer Center, University of Minnesota	Phase 2 / Phase 3
Completed	Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment NCT00499070	University Hospital Freiburg	—
Recruiting	Cancer in Inherited Bone Marrow Failure Syndromes NCT00027274	National Cancer Institute (NCI)	—
Completed	Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes NCT00004787	National Center for Research Resources (NCRR)	Phase 2
Available	Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blo NCT06731036	University of Florida	—